FTRE Quote, Financials, Valuation and Earnings

Illumina has a net margin of -4.13% compared to Fortrea Holdings's net margin of 65.28%. Fortrea Holdings's return on equity of -18.75% beat Illumina's return on equity of -37.83%.

Fortrea Holdings has a consensus price target of $23.29, signalling upside risk potential of 20.93%. On the other hand Illumina has an analysts' consensus of $148.36 which suggests that it could grow by 20.22%. Given that Fortrea Holdings has higher upside potential than Illumina, analysts believe Fortrea Holdings is more attractive than Illumina.

Fortrea Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Illumina has a beta of 1.105, suggesting its more volatile than the S&P 500 by 10.544%.

Fortrea Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Illumina offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortrea Holdings pays -- of its earnings as a dividend. Illumina pays out -- of its earnings as a dividend.

Fortrea Holdings quarterly revenues are $674.9M, which are smaller than Illumina quarterly revenues of $1.1B. Fortrea Holdings's net income of -$27.9M is lower than Illumina's net income of $705M. Notably, Fortrea Holdings's price-to-earnings ratio is -- while Illumina's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortrea Holdings is 0.58x versus 4.93x for Illumina. Usually stocks with elevated PS ratios are considered overvalued.

Lumos Pharma has a net margin of -4.13% compared to Fortrea Holdings's net margin of -1028.51%. Fortrea Holdings's return on equity of -18.75% beat Lumos Pharma's return on equity of -182.95%.

Fortrea Holdings has a consensus price target of $23.29, signalling upside risk potential of 20.93%. On the other hand Lumos Pharma has an analysts' consensus of -- which suggests that it could grow by 613.12%. Given that Lumos Pharma has higher upside potential than Fortrea Holdings, analysts believe Lumos Pharma is more attractive than Fortrea Holdings.

Fortrea Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Lumos Pharma has a beta of 0.742, suggesting its less volatile than the S&P 500 by 25.76%.

Fortrea Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lumos Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortrea Holdings pays -- of its earnings as a dividend. Lumos Pharma pays out -- of its earnings as a dividend.

Fortrea Holdings quarterly revenues are $674.9M, which are larger than Lumos Pharma quarterly revenues of $726K. Fortrea Holdings's net income of -$27.9M is lower than Lumos Pharma's net income of -$7.5M. Notably, Fortrea Holdings's price-to-earnings ratio is -- while Lumos Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortrea Holdings is 0.58x versus 16.57x for Lumos Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Medpace Holdings has a net margin of -4.13% compared to Fortrea Holdings's net margin of 18.08%. Fortrea Holdings's return on equity of -18.75% beat Medpace Holdings's return on equity of 54.64%.

Fortrea Holdings has a consensus price target of $23.29, signalling upside risk potential of 20.93%. On the other hand Medpace Holdings has an analysts' consensus of $347.92 which suggests that it could grow by 3.07%. Given that Fortrea Holdings has higher upside potential than Medpace Holdings, analysts believe Fortrea Holdings is more attractive than Medpace Holdings.

Fortrea Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Medpace Holdings has a beta of 1.367, suggesting its more volatile than the S&P 500 by 36.674%.

Fortrea Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Medpace Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortrea Holdings pays -- of its earnings as a dividend. Medpace Holdings pays out -- of its earnings as a dividend.

Fortrea Holdings quarterly revenues are $674.9M, which are larger than Medpace Holdings quarterly revenues of $533.3M. Fortrea Holdings's net income of -$27.9M is lower than Medpace Holdings's net income of $96.4M. Notably, Fortrea Holdings's price-to-earnings ratio is -- while Medpace Holdings's PE ratio is 29.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortrea Holdings is 0.58x versus 5.22x for Medpace Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Maravai LifeSciences Holdings has a net margin of -4.13% compared to Fortrea Holdings's net margin of -151.9%. Fortrea Holdings's return on equity of -18.75% beat Maravai LifeSciences Holdings's return on equity of -29.18%.

Fortrea Holdings has a consensus price target of $23.29, signalling upside risk potential of 20.93%. On the other hand Maravai LifeSciences Holdings has an analysts' consensus of $9.07 which suggests that it could grow by 68.8%. Given that Maravai LifeSciences Holdings has higher upside potential than Fortrea Holdings, analysts believe Maravai LifeSciences Holdings is more attractive than Fortrea Holdings.

Fortrea Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Maravai LifeSciences Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Fortrea Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Maravai LifeSciences Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortrea Holdings pays -- of its earnings as a dividend. Maravai LifeSciences Holdings pays out -- of its earnings as a dividend.

Fortrea Holdings quarterly revenues are $674.9M, which are larger than Maravai LifeSciences Holdings quarterly revenues of $65.2M. Fortrea Holdings's net income of -$27.9M is higher than Maravai LifeSciences Holdings's net income of -$99M. Notably, Fortrea Holdings's price-to-earnings ratio is -- while Maravai LifeSciences Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortrea Holdings is 0.58x versus 2.63x for Maravai LifeSciences Holdings. Usually stocks with elevated PS ratios are considered overvalued.